Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab™) in Adult Patients With Severe Sepsis and/or Septic Shock

NCT01145560 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01145560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01145560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab™) in Adult Patients With Severe Sepsis and/or Septic Shock
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2012
Enrollment
300 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock, severe sepsis